Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Poyurovsky, M. Articles by Weizman, A. Search for Related Content PubMed Citation Articles by Poyurovsky, M. Articles by Weizman, A. Atypical Neuroleptics Schizophrenia Spectrum Disorders

Attenuation of Olanzapine-Induced Weight Gain With Reboxetine in Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study

OBJECTIVE: Since increased norepinephrine availability may account for the weight-reducing effect of appetite suppressants, the authors hypothesized that the addition of the selective norepinephrine reuptake inhibitor reboxetine may prevent or attenuate olanzapine-induced weight gain. METHOD: Twenty-six patients hospitalized for first-episode DSM-IV schizophrenic disorder participated in the study. In addition to 6 weeks of treatment with olanzapine, 10 mg/day, patients were randomly allocated in a double-blind design to receive either reboxetine, 4 mg/day, (N=13) or placebo (N=13). RESULTS: Ten patients in each group completed the 6-week trial. Patients given olanzapine and reboxetine demonstrated a significantly lower increase in body weight (mean=2.5 kg, SD=2.7) than those given olanzapine and placebo (mean=5.5 kg, SD=3.1). Significantly fewer patients in the olanzapine/reboxetine group (N=2 of 10) than in the olanzapine/placebo group (N=7 of 10) gained at least 7% of their initial weight, the cutoff for clinically significant weight gain. The addition of reboxetine to olanzapine treatment was safe and well tolerated by the patients. A between-group difference in the reduction of Hamilton depression scale scores was seen that favored the olanzapine/reboxetine group (mean difference=–3.1, SD=1.25). CONCLUSIONS: The selective norepinephrine reuptake inhibitor reboxetine may reduce olanzapine-induced weight gain in schizophrenia patients, and activation of the adrenergic system may attenuate weight gain induced by atypical antipsychotic agents.

This article has been cited by other articles:

				M. Malone Medications Associated with Weight Gain Ann. Pharmacother., December 1, 2005; 39(12): 2046 - 2054. [Abstract] [Full Text] [PDF]

				D. C. Henderson, P. M. Copeland, T. B. Daley, C. P. Borba, C. Cather, D. D. Nguyen, P. M. Louie, A. E. Evins, O. Freudenreich, D. Hayden, et al. A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain Am J Psychiatry, May 1, 2005; 162(5): 954 - 962. [Abstract] [Full Text] [PDF]

				E K. Hester and M. R Thrower Current Options in the Management of Olanzapine-Associated Weight Gain Ann. Pharmacother., February 1, 2005; 39(2): 302 - 310. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us